Precision Medicine
Precision medicine tailors treatments to the needs of individual patients by considering genetic, environmental and lifestyle factors. They can target the underlying causes of a patient’s condition, improve effectiveness, and reduce side effects.
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for…
The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’
3 December 2020
Bernarda Zamora presented at the virtual event entitled ‘Value of Diagnostic Information in Heart Failure’, which was organised by Roche Diagnostics. The panel, composed of six…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin,…
Personalised Medicine: is it an Oil-Rush or Oil-Spill?
1 May 2020
Personalised medicine, also known as ‘precision’ or ‘stratified’ medicine, targets treatment by using genetics and/or biomarkers to identify patients or subgroups of patients who have distinct…
Our Contributions to the Economics of Personalised Medicine
7 March 2018
OHE has authored numerous papers on personalised medicine with contributions to value frameworks, innovations in pricing and cost effectiveness analyses.
Value and Cancer: Journal of Cancer Policy Special Issue
25 January 2017
A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.
OHE’s Paula Lorgelly Appointed as a Visiting Professor at King’s College London
20 June 2016
Paula Lorgelly has accepted an appointment as a Visiting Professor in the Division of Cancer Studies at King’s College London.
OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
29 October 2014
ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The…